American vaccine development company Novavax has announced the start of clinical trials for its proposed COVID-19 vaccine, which will be administered to a juvenile population.
According to the company’s notification, the trials will be comprised of 3,000 individuals – that will be aged 12 to 17 years old. The population will be separated into two groups – with one receiving the shot and the other a placebo.
The shots are going to be administered 21 days apart with participants being monitored for two years after being inoculated.
Novavax said they’re going to test for the ‘efficacy’ and ‘safety’ of their vaccine, which hasn’t been approved for use in any country – even for adults.
Although this is the case, the biotech firm is planning to file an emergency use authorization in Britain some time this 2021. After that, they’ll seek approval in the US.
The vaccine manufacturer has previously conducted trials in Britain, which they made public back in January. The trial had a population of 15,000 – all adults – and revealed that the jab is 89.9 percent effective.
Novavax’s shot is a protein-based vaccine that teaches the immune system to develop antibodies against the coronavirus.
Besides, Novavax other biotech firms have also announced juvenile trials for their respective vaccines, specifically Pfizer-BioNTech, Moderna, and Johnsons & Johnsons.
In the Philippines, so far, six vaccines have been given emergency use authorizations (EUAs) by the Food and Drug Administration (FDA) – Pfizer, AstraZeneca, Coronavac, Sputnik V, Janssen, and Covaxin.
And out of all of these, two have conducted clinical trials in the Philippines – specifically Janssen, Coronavac. Apart from these two, China’s Clover vaccine has also been approved for trials in the country, however, it hasn’t been given an EUA.
Want more news like this one? Head over to Nation Builder PH Breaking News Section for the latest updates.
Image credit: Justin Tallis / AFP via Getty Images